Tagged with NCI

USA As the world’s largest stock exchange, the New York Stock Exchange (NYSE) plays a pivotal role in shaping access to capital for healthcare and life sciences companies. Johanna Grossman, PhD, who leads this sector for the NYSE, reflects on her career path, the exchange’s growing footprint in biotech, and the…

Denmark Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. And with life science exports surpassing EUR 23 billion last year…

USA The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial after patient death; Courts half another attempt to challenge the IRA’s negation program; Takeda scoops up former Lilly exec to…

Denmark As European biotech continues to navigate tightening capital markets and increasing global competition, Kurma Partners is doubling down on its core belief: that world-class innovation can, and should, be built and scaled from within Europe. Managing Partner Rémi Droller shares how Kurma’s investment model combines early-stage company creation with long-term…

Puerto Rico Across over 50 interviews with Puerto Rican government and industry stakeholders, energy supply was continuously identified as the main barrier to growth. Puerto Rico’s ageing, centralised, and fossil fuel–dependent power system remains vulnerable to disruption from hurricanes and other natural events. However, new investments in renewables, battery storage, and decentralised…

Denmark Hans Schambye brings decades of experience across academia, biotech start-ups, and industry leadership. Now CEO of Galecto – which develops small molecules for the treatment of cancer and severe liver disease – and chairman of DANISH BIO, he has led clinical development, financing, and partnerships in both Europe and the…

Denmark Since stepping into the role of Chair of the Danish Medicines Council in early 2025, Birgitte Klindt Poulsen has been navigating the delicate balance between accelerating patient access to innovation and maintaining the rigour of independent, evidence-based evaluation. In this interview, she shares how the Council is adapting to a…

Netherlands Philip Scheltens, Professor of Neurology and Partner and Head of the EQT Life Sciences Dementia Fund, reflects on the journey from founding the world’s first dedicated neurodegeneration investment fund to building a strong pipeline of promising companies, backed by scientific rigour, biomarker innovation and partnerships with major pharmaceutical firms. With…

Puerto Rico Carlos Ceinos, President & Co-Founder of Principia, leads a Puerto Rico-based consulting firm focused on automation, MES, project management, and validation for the biopharmaceutical industry. Since 2019, the company has doubled in size and expanded into the U.S. and Canada, driven by expertise, trust, and flexibility. Now entering a management…

Investment In a year marked by uncertainty and tighter capital flows, the competition to attract life sciences investment has never been fiercer. Global hubs are not just showcasing infrastructure or talent – they’re fighting for the soul, and pockets, of the industry’s future. We spoke to the CEOs of regional investment…

Puerto Rico DECA is a consulting firm founded in 2022, focused on helping businesses in Puerto Rico access non-dilutive financing incentives, such as federal grants, local grants, and monetizable R&D tax credits. The firm leverages Puerto Rico’s unique financial framework, including Act 60, to streamline the process for both local and foreign…

China Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by blacklisting the American gene sequencing giant. But beyond the implications for the company, as the trade conflict continues to rage…